You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePantoprazole
Accession NumberDB00213  (APRD00073)
TypeSmall Molecule
GroupsApproved
DescriptionPantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.
Structure
Thumb
Synonyms
Pantoprazol
Pantoprazolum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-pantoprazoletablet (delayed-release)40 mgoralAbbott Laboratories, Limited2014-03-172015-12-31Canada
Abbott-pantoprazoletablet (delayed-release)20 mgoralAbbott Laboratories, LimitedNot applicableNot applicableCanada
Act Pantoprazoletablet (delayed-release)40 mgoralActavis Pharma Company2008-06-04Not applicableCanada
Auro-pantoprazoletablet (delayed-release)40 mgoralAuro Pharma Inc2016-02-06Not applicableCanada
Ava-pantoprazoletablet (delayed-release)40 mgoralAvanstra Inc2011-09-192014-08-21Canada
Ava-pantoprazoletablet (delayed-release)20 mgoralAvanstra Inc2011-09-192014-08-21Canada
Controloc ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Controloc ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Controloc ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Controloc ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Dom-pantoprazolepowder for solution40 mgintravenousDominion PharmacalNot applicableNot applicableCanada
Dom-pantoprazoletablet (delayed-release)20 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-pantoprazoletablet (delayed-release)40 mgoralDominion Pharmacal2012-10-25Not applicableCanada
Ipg-pantoprazoletablet (delayed-release)40 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-pantoprazoletablet (delayed-release)20 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-pantoprazoletablet (delayed-release)40 mgoralJamp Pharma Corporation2014-12-12Not applicableCanada
Jamp-pantoprazoletablet (delayed-release)20 mgoralJamp Pharma Corporation2014-02-11Not applicableCanada
Mar-pantoprazoletablet (delayed-release)40 mgoralMarcan Pharmaceuticals Inc2014-07-18Not applicableCanada
Mar-pantoprazoletablet (delayed-release)20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-pantoprazoletablet (delayed-release)40 mgoralMint Pharmaceuticals Inc2014-01-16Not applicableCanada
Mint-pantoprazoletablet (delayed-release)20 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-pantoprazoletablet (delayed-release)40 mgoralMylan Pharmaceuticals Ulc2008-06-03Not applicableCanada
Ntp-pantoprazoletablet (delayed-release)20 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-pantoprazoletablet (delayed-release)40 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Pantecta ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Pantecta ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Pantecta ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Pantecta ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Panto IVpowder for solution40 mgintravenousTakeda Canada Inc1999-04-06Not applicableCanada
Panto-byktablet (enteric-coated)40 mgoralNycomed GmbhNot applicableNot applicableCanada
Panto-byktablet (enteric-coated)20 mgoralNycomed GmbhNot applicableNot applicableCanada
Pantoloctablet (enteric-coated)20 mgoralTakeda Canada Inc2000-05-02Not applicableCanada
Pantoloctablet (enteric-coated)40 mgoralTakeda Canada Inc1997-03-05Not applicableCanada
Pantoloc ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Pantoloc ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Pantoloc ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Pantoloc ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Pantoprazoletablet (delayed-release)20 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Pantoprazoletablet (delayed-release)40 mgoralLaboratoire Riva Inc2014-10-16Not applicableCanada
Pantoprazoletablet (delayed-release)40 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Pantoprazoletablet (delayed-release)40 mgoralSanis Health Inc2011-09-13Not applicableCanada
Pantoprazoletablet (delayed-release)40 mgoralPharmascience Inc2015-05-20Not applicableCanada
Pantoprazoletablet (delayed-release)20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pantoprazoletablet (delayed-release)40 mgoralPro Doc Limitee2009-01-29Not applicableCanada
Pantoprazoletablet (delayed-release)40 mgoralDominion Pharmacal2015-10-30Not applicableCanada
Pantoprazoletablet (delayed-release)20 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Pantoprazoletablet (delayed-release)20 mgoralMeliapharm Inc2009-08-282014-06-25Canada
Pantoprazoletablet (delayed-release)40 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pantoprazoletablet (delayed-release)40 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Pantoprazoletablet (delayed-release)40 mgoralMeliapharm Inc2009-08-282014-06-25Canada
Pantoprazoletablet (delayed-release)40 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Pantoprazole for Injectionpowder for solution40 mgintravenousTeva Canada Limited2010-05-17Not applicableCanada
Pantoprazole for Injectionpowder for solution40 mgintravenousFresenius Kabi Canada Ltd2010-12-14Not applicableCanada
Pantoprazole Magnesiumtablet (enteric-coated)40 mgoralAspri Pharma Canada Inc2015-11-25Not applicableCanada
Pantoprazole Sodium Delayed Releasetablet, delayed release20 mg/1oralSTAT Rx USA LLC2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releasetablet, delayed release40 mg/1oralPreferred Pharmaceuticals, Inc.2014-02-06Not applicableUs
Pantoprazole Sodium Delayed-releasetablet, delayed release20 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releasetablet, delayed release20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releasetablet, delayed release40 mg/1oralCardinal Health2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releasetablet, delayed release40 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releasetablet, delayed release20 mg/1oralProficient Rx2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releasetablet, delayed release40 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releasetablet, delayed release40 mg/1oralCardinal Health2008-01-312016-03-22Us
Pantoprazole Sodium Delayed-releasetablet, delayed release40 mg/1oralContract Pharmacy Services Pa2010-02-26Not applicableUs
Pantoprazole Sodium Delayed-release Delayed-releasetablet, delayed release40 mg/1oralSt Marys Medical Park Pharmacy2014-05-23Not applicableUs
Pantoprazole Sodium for Injectionpowder for solution40 mgintravenousSandoz Canada Incorporated2008-03-11Not applicableCanada
Pantoprazole Sodium for Injectionpowder for solution40 mgintravenousGeneric Medical Partners IncNot applicableNot applicableCanada
Pantoprazole Sodium for Injectionpowder for solution40 mgintravenousAccord Healthcare IncNot applicableNot applicableCanada
Pantoprazole Sodium for Injectionpowder for solution40 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Pantoprazole Sodiumdelayed-release Delayed-releasetablet, delayed release40 mg/1oralPd Rx Pharmaceuticals, Inc.2008-01-31Not applicableUs
Pantoprazole-20tablet (delayed-release)20 mgoralSivem Pharmaceuticals Ulc2014-07-21Not applicableCanada
Pantoprazole-40tablet (delayed-release)40 mgoralSivem Pharmaceuticals Ulc2014-07-21Not applicableCanada
Pantozol ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Pantozol ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Pantozol ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Pantozol ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
PHL-pantoprazolepowder for solution40 mgintravenousPharmel IncNot applicableNot applicableCanada
PMS-pantoprazolepowder for solution40 mgintravenousPharmascience Inc2007-04-03Not applicableCanada
PMS-pantoprazoletablet (delayed-release)20 mgoralPharmascience Inc2008-06-04Not applicableCanada
PMS-pantoprazoletablet (delayed-release)40 mgoralPharmascience Inc2008-06-04Not applicableCanada
Priva-pantoprazoletablet (delayed-release)40 mgoralPharmapar Inc2015-01-13Not applicableCanada
Protonixtablet, delayed release40 mg/1oralRebel Distributors Corp2001-08-28Not applicableUs
Protonix Delayed-releasegranule, delayed release40 mg/1oralCardinal Health2008-02-29Not applicableUs
Protonix Delayed-releasetablet, delayed release20 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-17Not applicableUs
Protonix Delayed-releasegranule, delayed release40 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2008-02-29Not applicableUs
Protonix Delayed-releasetablet, delayed release40 mg/1oralPhysicians Total Care, Inc.2001-08-28Not applicableUs
Protonix Delayed-releasetablet, delayed release40 mg/1oralAvera Mc Kennan Hospital2015-09-21Not applicableUs
Protonix Delayed-releasetablet, delayed release20 mg/1oralCardinal Health2000-05-01Not applicableUs
Protonix Delayed-releasetablet, delayed release40 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2000-05-01Not applicableUs
Protonix Delayed-releasetablet, delayed release20 mg/1oralPhysicians Total Care, Inc.2003-05-02Not applicableUs
Protonix Delayed-releasetablet, delayed release20 mg/1oralSTAT Rx USA LLC2000-05-01Not applicableUs
Protonix Delayed-releasetablet, delayed release40 mg/1oralCardinal Health2000-05-01Not applicableUs
Protonix Delayed-releasetablet, delayed release20 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2000-05-01Not applicableUs
Protonix Delayed-releasetablet, delayed release40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-17Not applicableUs
Protonix I.V.injection, powder, for solution40 mg/10mLintravenousWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2014-03-17Not applicableUs
Protonix I.V.injection, powder, for solution40 mg/10mLintravenousCardinal Health2001-05-01Not applicableUs
Protonix I.V.injection, powder, for solution40 mg/10mLintravenousWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2013-05-01Not applicableUs
Protonix I.V.injection, powder, for solution40 mg/10mLintravenousWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2001-05-01Not applicableUs
Protonix I.V.injection, powder, for solution40 mg/10mLintravenousCardinal Health2001-05-01Not applicableUs
Protonix I.V.injection, powder, for solution40 mg/10mLintravenousWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2001-05-01Not applicableUs
Protonix I.V.injection, powder, for solution40 mg/10mLintravenousCardinal Health2001-05-01Not applicableUs
Q-pantoprazoletablet (delayed-release)40 mgoralQd Pharmaceuticals Ulc2011-10-032015-08-21Canada
Ran-pantoprazoletablet (delayed-release)20 mgoralRanbaxy Pharmaceuticals Canada Inc.2008-02-12Not applicableCanada
Ran-pantoprazoletablet (delayed-release)40 mgoralRanbaxy Pharmaceuticals Canada Inc.2008-02-12Not applicableCanada
Ratio-pantoprazoletablet (delayed-release)40 mgoralRatiopharm Inc Division Of Teva Canada Limited2008-06-032015-10-26Canada
Ratio-pantoprazoletablet (delayed-release)20 mgoralRatiopharm Inc Division Of Teva Canada Limited2008-06-032015-10-26Canada
Riva-pantoprazoletablet (delayed-release)40 mgoralLaboratoire Riva Inc2008-10-27Not applicableCanada
Riva-pantoprazoletablet (delayed-release)20 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Sandoz Pantoprazoletablet (delayed-release)20 mgoralSandoz Canada Incorporated2008-06-03Not applicableCanada
Sandoz Pantoprazoletablet (delayed-release)40 mgoralSandoz Canada Incorporated2008-06-03Not applicableCanada
Somac ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Somac ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Somac ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Somac ControlGastro-resistant tablet20 mgOral useTakeda Gmb H2009-06-12Not applicableEu
Tectatablet (enteric-coated)40 mgoralTakeda Canada Inc2006-03-15Not applicableCanada
Teva-pantoprazoletablet (delayed-release)40 mgoralTeva Canada Limited2008-04-11Not applicableCanada
Teva-pantoprazoletablet (delayed-release)20 mgoralTeva Canada Limited2008-04-11Not applicableCanada
Teva-pantoprazole Magnesiumtablet (delayed-release)40 mgoralTeva Canada Limited2015-11-16Not applicableCanada
Torrent-pantoprazoletablet (delayed-release)40 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-pantoprazoletablet (delayed-release)20 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Van-pantoprazoletablet (delayed-release)40 mgoralVanc Pharmaceuticals Inc2015-11-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pantoprazoletablet (delayed-release)20 mgoralApotex Inc2008-03-05Not applicableCanada
Apo-pantoprazoletablet (delayed-release)40 mgoralApotex Inc2008-03-05Not applicableCanada
Pantoprazoletablet, delayed release40 mg/1oralCardinal Health2011-01-19Not applicableUs
Pantoprazoletablet, delayed release20 mg/1oralDr.Reddy's Laboratories Limited2011-01-19Not applicableUs
Pantoprazoletablet, delayed release20 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Pantoprazoletablet, delayed release40 mg/1oralDr.Reddy's Laboratories Limited2011-01-19Not applicableUs
Pantoprazoletablet, delayed release40 mg/1oralLegacy Pharmaceutical Packaging2011-01-19Not applicableUs
Pantoprazoletablet, delayed release40 mg/1oralMajor Pharmaceuticals2011-01-19Not applicableUs
Pantoprazoletablet, delayed release40 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralPd Rx Pharmaceuticals, Inc.2015-05-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralMajor Pharmaceuticals2015-06-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-09-10Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralKremers Urban Pharmaceuticals Inc.2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralUnit Dose Services2007-09-10Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralAurobindo Pharma Limited2012-09-28Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralPreferred Pharmaceuticals, Inc.2014-03-05Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralREMEDYREPACK INC.2015-09-04Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralMacleods Pharmaceuticals Limited2011-12-03Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralTeva Pharmaceuticals USA Inc2007-12-21Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralREMEDYREPACK INC.2014-02-182016-04-05Us
Pantoprazole Sodiumtablet, delayed release40 mg/1oralREMEDYREPACK INC.2015-01-12Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralREMEDYREPACK INC.2011-11-15Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralRanbaxy Pharmaceuticals Inc.2012-05-02Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralLegacy Pharmaceutical Packaging, Llc2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralRebel Distributors Corp2010-10-12Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralPhysicians Total Care, Inc.2009-06-03Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralJubilant Cadista Pharmaceuticals Inc.2011-09-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralProficient Rx LP2011-02-08Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralAmerican Health Packaging2013-08-26Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralAmerican Health Packaging2013-05-152015-12-29Us
Pantoprazole Sodiumtablet, delayed release40 mg/1oralActavis Inc.2011-02-08Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-01-23Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralWockhardt Limited2011-01-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralDIRECT RX2014-01-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralAv Pak2013-01-15Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralReady Meds2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralPreferred Pharmaceuticals, Inc.2014-12-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralAv Kare, Inc.2016-02-22Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralOrchid Pharma Inc2015-03-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralPreferred Pharmaceuticals, Inc.2013-11-18Not applicableUs
Pantoprazole Sodiuminjection, powder, for solution40 mg/1intravenousAuro Medics Pharma Llc2016-03-30Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralAphena Pharma Solutions Tennessee, Inc.2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralTorrent Pharmaceuticals Limited2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralClinical Solutions Wholesale, Llc2007-12-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralKremers Urban Pharmaceuticals Inc.2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralUnit Dose Services2011-01-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralAurobindo Pharma Limited2012-09-28Not applicableUs
Pantoprazole Sodiumtablet40 mg/1oralREMEDYREPACK INC.2011-11-15Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralbryant ranch prepack2007-12-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralLegacy Pharmaceutical Packaging, Llc2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralCardinal Health2015-05-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralRx Change Co.2007-12-21Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralTeva Pharmaceuticals USA Inc2007-12-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralREMEDYREPACK INC.2014-04-24Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralCardinal Health2013-01-15Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralREMEDYREPACK INC.2015-02-26Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralCamber Pharmaceuticals, Inc.2014-09-10Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralJubilant Cadista Pharmaceuticals Inc.2011-09-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralProficient Rx LP2007-12-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralREMEDYREPACK INC.2013-05-15Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralAmerican Health Packaging2014-12-16Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralAmerican Health Packaging2012-03-012016-01-01Us
Pantoprazole Sodiumtablet, delayed release20 mg/1oralSun Pharma Global FZE2007-09-10Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-12-21Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralWockhardt Limited2011-01-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralDIRECT RX2015-01-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralAv Pak2013-01-15Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralWockhardt USA LLC.2011-01-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralPreferred Pharmaceuticals, Inc.2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralProficient Rx LP2014-09-10Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralOrchid Pharma Inc2015-03-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralSun Pharmaceutical Industries Limited2014-12-15Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralMylan Institutional Inc.2011-02-23Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralPrasco Laboratories2015-05-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralPreferred Pharmaceuticals, Inc.2013-08-22Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralMedsource Pharmaceuticals2007-12-21Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralTorrent Pharmaceuticals Limited2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralClinical Solutions Wholesale2011-02-08Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralCardinal Health2012-09-05Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralREMEDYREPACK INC.2015-10-09Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralREMEDYREPACK INC.2011-12-02Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralbryant ranch prepack2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralLegacy Pharmaceutical Packaging, Llc2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralLegacy Pharmaceutical Packaging, Llc2011-01-202016-02-29Us
Pantoprazole Sodiumtablet, delayed release20 mg/1oralMylan Pharmaceuticals Inc.2011-01-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralREMEDYREPACK INC.2014-06-11Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralSun Pharma Global FZE2007-09-10Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralCamber Pharmaceuticals, Inc.2014-09-10Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralSt Marys Medical Park Pharmacy2013-08-08Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralProficient Rx LP2007-12-21Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralREMEDYREPACK INC.2013-05-24Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralRebel Distributors Corp2007-09-10Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-04-10Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralKremers Urban Pharmaceuticals Inc.2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralAv Pak2015-01-30Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralWockhardt USA LLC.2011-01-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralPreferred Pharmaceuticals, Inc.2014-02-18Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralCardinal Health2015-06-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralPhysicians Total Care, Inc.2008-01-02Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralSun Pharmaceutical Industries Limited2014-12-15Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralPrasco Laboratories2015-05-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralAmerican Health Packaging2013-05-152015-12-29Us
Pantoprazole Sodiumtablet, delayed release20 mg/1oralActavis Inc.2011-02-08Not applicableUs
Pantoprazole Sodiuminjection, powder, for solution40 mg/1intravenousAkorn, Inc.2012-11-082016-02-05Us
Pantoprazole Sodiumtablet, delayed release40 mg/1oralMylan Pharmaceuticals Inc.2011-01-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralCardinal Health2012-01-23Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralDIRECT RX2014-01-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralREMEDYREPACK INC.2013-02-08Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-01-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralPreferred Pharmaceuticals, Inc.2014-12-01Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralAv Kare, Inc.2016-02-22Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-19Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralSafecor Health, LLC2014-09-30Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralMacleods Pharmaceuticals Limited2011-12-03Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralCardinal Health2011-02-07Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralREMEDYREPACK INC.2014-12-26Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralRanbaxy Pharmaceuticals Inc.2012-05-02Not applicableUs
Pantoprazole Sodiumtablet, delayed release20 mg/1oralREMEDYREPACK INC.2014-02-20Not applicableUs
Pantoprazole Sodiumtablet, delayed release40 mg/1oralLegacy Pharmaceutical Packaging2011-01-20Not applicableUs
Pantoprazole Sodium Delayed Releasetablet40 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Pantoprazole Sodium Delayed Releasetablet, delayed release40 mg/1oralNorthwind Pharmaceuticals2014-03-21Not applicableUs
Pantoprazole Sodium Drtablet, delayed release40 mg/1oralNorthwind Pharmaceuticals, LLC2014-07-16Not applicableUs
Pantoprazole Sodium Drtablet, delayed release40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-01-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PantozolNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pantoprazole Magnesium
ThumbNot applicableDBSALT000853
Pantoprazole Sodium
138786-67-1
Thumb
  • InChI Key: YNWDKZIIWCEDEE-UHFFFAOYNA-N
  • Monoisotopic Mass: 405.057077726
  • Average Mass: 405.352
DBSALT000386
Categories
UNIID8TST4O562
CAS number102625-70-7
WeightAverage: 383.37
Monoisotopic: 383.075133083
Chemical FormulaC16H15F2N3O4S
InChI KeyInChIKey=IQPSEEYGBUAQFF-UHFFFAOYSA-N
InChI
InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
IUPAC Name
6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole
SMILES
COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassSulfinylbenzimidazoles
Direct ParentSulfinylbenzimidazoles
Alternative Parents
Substituents
  • Sulfinylbenzimidazole
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Sulfoxide
  • Azacycle
  • Sulfinyl compound
  • Ether
  • Halomethane
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationShort-term (up to 16 weeks) treatment of erosive esophagitis.
PharmacodynamicsPantoprazole is a substituted benzimidazole indicated for the short-term treatment (up to 16 weeks) in the healing and symptomatic relief of erosive esophagitis. Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production.
Mechanism of actionPantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by forming a covalent bond to two sites of the (H+,K+ )- ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect is dose- related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.
Related Articles
AbsorptionPantoprazole is well absorbed. It undergoes little first-pass metabolism resulting in an absolute bioavailability of approximately 77%.
Volume of distribution
  • 11.0 to 23.6 L
Protein binding98%
Metabolism

Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity.

SubstrateEnzymesProduct
Pantoprazole
Not Available
Active Metabolite of PantoprazoleDetails
Route of eliminationAfter administration of a single intravenous dose of 14C-labeled pantoprazole to healthy, normal metabolizer subjects, approximately 71% of the dose was excreted in the urine with 18% excreted in the feces through biliary excretion.
Half life1 hour
Clearance
  • 7.6-14.0 L/h
ToxicitySingle intravenous doses of pantoprazole at 378, 230, and 266 mg/kg (38, 46, and 177 times the recommended human dose based on body surface area) were lethal to mice, rats and dogs, respectively. The symptoms of toxicity included hypoactivity, ataxia, hunched sitting, limb-splay, lateral position, segregation, absence of ear reflex, and tremor. There is limited experience regarding cases of human overdosage, and treatment should be symptomatic and supportive.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Pantoprazole Action PathwayDrug actionSMP00228
Pantoprazole Metabolism PathwayDrug metabolismSMP00615
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9935
Blood Brain Barrier-0.5777
Caco-2 permeable+0.7262
P-glycoprotein substrateNon-substrate0.6127
P-glycoprotein inhibitor IInhibitor0.5587
P-glycoprotein inhibitor IINon-inhibitor0.9198
Renal organic cation transporterNon-inhibitor0.6285
CYP450 2C9 substrateNon-substrate0.84
CYP450 2D6 substrateNon-substrate0.8683
CYP450 3A4 substrateSubstrate0.7254
CYP450 1A2 substrateInhibitor0.7639
CYP450 2C9 inhibitorNon-inhibitor0.8054
CYP450 2D6 inhibitorNon-inhibitor0.7308
CYP450 2C19 inhibitorInhibitor0.7877
CYP450 3A4 inhibitorNon-inhibitor0.7258
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.903
Ames testNon AMES toxic0.5527
CarcinogenicityNon-carcinogens0.8108
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.3466 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9228
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Wyeth pharmaceuticals inc
  • Kudco ireland ltd
  • Sun pharma global inc
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Gastro-resistant tabletOral use20 mg
Powder for solutionintravenous40 mg
Tablet (enteric-coated)oral20 mg
Tablet (enteric-coated)oral40 mg
Injection, powder, for solutionintravenous40 mg/1
Tabletoral40 mg/1
Tablet, delayed releaseoral20 mg/1
Tablet, delayed releaseoral40 mg/1
Granule, delayed releaseoral40 mg/1
Injection, powder, for solutionintravenous40 mg/10mL
Tablet (delayed-release)oral20 mg
Tablet (delayed-release)oral40 mg
Prices
Unit descriptionCostUnit
Protonix iv 40 mg vial14.4USD vial
Protonix 40 mg tablet dr8.91USD tablet
Protonix 20 mg tablet5.43USD tab
Protonix 40 mg Enteric Coated Tabs5.43USD tab
Protonix dr 20 mg tablet5.22USD tablet
Protonix dr 40 mg tablet5.22USD tablet
Pantoprazole Sodium 20 mg Enteric Coated Tabs4.26USD tab
Pantoprazole Sodium 40 mg Enteric Coated Tabs4.26USD tab
Pantoprazole sod dr 20 mg tablet3.93USD tablet
Pantoprazole sod dr 40 mg tablet3.93USD tablet
Pantoloc 40 mg Enteric-Coated Tablet2.28USD tablet
Apo-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Co Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Mylan-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Novo-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Phl-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Pms-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Ran-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Ratio-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Sandoz Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2092694 No2005-04-052011-09-06Canada
CA2341031 No2006-04-042019-08-12Canada
CA2428870 No2006-05-232021-11-17Canada
US4758579 No1993-07-192010-07-19Us
US5997903 Yes1997-06-072017-06-07Us
US6780881 Yes2002-05-172022-05-17Us
US7351723 Yes2002-05-172022-05-17Us
US7544370 Yes2006-12-072026-12-07Us
US7550153 Yes2005-03-302025-03-30Us
US7553498 Yes2005-03-302025-03-30Us
US7838027 Yes2005-03-302025-03-30Us
US8754108 Yes2002-05-172022-05-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting pointBecause of gradual degradation of pantoprazole sodium during heating, the melting point cannot be determined.Not Available
water solubilityFreely soluble in water.Not Available
logP0.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.495 mg/mLALOGPS
logP2.11ALOGPS
logP2.18ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)9.15ChemAxon
pKa (Strongest Basic)3.55ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area86.33 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity90.05 m3·mol-1ChemAxon
Polarizability35.17 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Rudolf Linder, “Freeze-dried pantoprazole preparation and pantoprazole injection.” U.S. Patent US20030003058, issued January 02, 2003.

US20030003058
General ReferencesNot Available
External Links
ATC CodesA02BD04A02BD11A02BC02
AHFS Codes
  • 56:28.36
PDB EntriesNot Available
FDA labelDownload (183 KB)
MSDSDownload (58.1 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Pantoprazole can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Pantoprazole.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Pantoprazole.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Pantoprazole.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Pantoprazole.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Pantoprazole.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Pantoprazole.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Pantoprazole.
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Pantoprazole.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Pantoprazole.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Pantoprazole.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Pantoprazole.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Pantoprazole.
AmiodaroneThe metabolism of Pantoprazole can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Pantoprazole.
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Pantoprazole.
AmphetaminePantoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Pantoprazole.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Pantoprazole.
AprepitantThe serum concentration of Pantoprazole can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Pantoprazole.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Pantoprazole.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Pantoprazole.
ArmodafinilThe metabolism of Pantoprazole can be decreased when combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Pantoprazole.
ArtemetherThe metabolism of Artemether can be decreased when combined with Pantoprazole.
AtazanavirThe metabolism of Pantoprazole can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Pantoprazole.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Pantoprazole.
AtomoxetineThe metabolism of Pantoprazole can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Pantoprazole.
AzelastineThe metabolism of Azelastine can be decreased when combined with Pantoprazole.
AzithromycinThe metabolism of Pantoprazole can be decreased when combined with Azithromycin.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Pantoprazole.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Pantoprazole.
BexaroteneThe serum concentration of Pantoprazole can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Pantoprazole can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Pantoprazole.
BortezomibThe metabolism of Pantoprazole can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Pantoprazole can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Pantoprazole.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pantoprazole.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Pantoprazole.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Pantoprazole.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Pantoprazole.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Pantoprazole.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Pantoprazole.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Pantoprazole.
CaffeineThe metabolism of Pantoprazole can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Pantoprazole.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Pantoprazole.
CarbamazepineThe metabolism of Pantoprazole can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Pantoprazole.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Pantoprazole.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Pantoprazole.
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Pantoprazole.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Pantoprazole.
CeritinibThe serum concentration of Pantoprazole can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Pantoprazole.
ChloramphenicolThe metabolism of Pantoprazole can be decreased when combined with Chloramphenicol.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Pantoprazole.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Pantoprazole.
CholecalciferolThe metabolism of Pantoprazole can be decreased when combined with Cholecalciferol.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Pantoprazole.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Pantoprazole.
CimetidineThe metabolism of Pantoprazole can be decreased when combined with Cimetidine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Pantoprazole.
CisaprideThe metabolism of Cisapride can be decreased when combined with Pantoprazole.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Pantoprazole.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Pantoprazole.
CitalopramThe metabolism of Pantoprazole can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Pantoprazole can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Pantoprazole.
ClemastineThe metabolism of Pantoprazole can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Pantoprazole.
ClodronateThe therapeutic efficacy of Clodronate can be decreased when used in combination with Pantoprazole.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Pantoprazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Pantoprazole.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Pantoprazole.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Pantoprazole.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Pantoprazole.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Pantoprazole.
ClotrimazoleThe metabolism of Pantoprazole can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Pantoprazole.
CobicistatThe metabolism of Pantoprazole can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Pantoprazole.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Pantoprazole.
ConivaptanThe serum concentration of Pantoprazole can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Pantoprazole.
CrizotinibThe metabolism of Pantoprazole can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Pantoprazole.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Pantoprazole.
CyclosporineThe metabolism of Pantoprazole can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Pantoprazole.
Cyproterone acetateThe serum concentration of Pantoprazole can be decreased when it is combined with Cyproterone acetate.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Pantoprazole.
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Pantoprazole resulting in a loss in efficacy.
DabrafenibThe serum concentration of Pantoprazole can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Pantoprazole.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Pantoprazole.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Pantoprazole.
DapsoneThe metabolism of Dapsone can be decreased when combined with Pantoprazole.
DarunavirThe metabolism of Pantoprazole can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Pantoprazole can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Pantoprazole.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Pantoprazole.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Pantoprazole.
DeferasiroxThe serum concentration of Pantoprazole can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Pantoprazole.
DelavirdineThe metabolism of Pantoprazole can be decreased when combined with Delavirdine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Pantoprazole.
DexamethasoneThe serum concentration of Pantoprazole can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Pantoprazole.
DexmethylphenidatePantoprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextroamphetaminePantoprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Pantoprazole.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Pantoprazole.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Pantoprazole.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Pantoprazole.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Pantoprazole.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Pantoprazole.
DihydroergotamineThe metabolism of Pantoprazole can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Pantoprazole.
DiltiazemThe metabolism of Pantoprazole can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Pantoprazole.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Pantoprazole.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Pantoprazole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Pantoprazole.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Pantoprazole.
DopamineThe metabolism of Dopamine can be decreased when combined with Pantoprazole.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Pantoprazole.
DoxepinThe metabolism of Doxepin can be decreased when combined with Pantoprazole.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Pantoprazole.
DoxycyclineThe metabolism of Pantoprazole can be decreased when combined with Doxycycline.
DronabinolThe metabolism of Dronabinol can be decreased when combined with Pantoprazole.
DronedaroneThe metabolism of Pantoprazole can be decreased when combined with Dronedarone.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Pantoprazole.
EfavirenzThe serum concentration of Pantoprazole can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Pantoprazole.
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Pantoprazole.
EnzalutamideThe serum concentration of Pantoprazole can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Pantoprazole.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Pantoprazole.
ErythromycinThe metabolism of Pantoprazole can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Pantoprazole.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Pantoprazole.
Eslicarbazepine acetateThe serum concentration of Pantoprazole can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Pantoprazole.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Pantoprazole.
EstriolThe serum concentration of Estriol can be increased when it is combined with Pantoprazole.
EstroneThe serum concentration of Estrone can be increased when it is combined with Pantoprazole.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pantoprazole.
Etidronic acidThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Pantoprazole.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Pantoprazole.
EtravirineThe serum concentration of Pantoprazole can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Pantoprazole.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Pantoprazole.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Pantoprazole.
FamotidineThe metabolism of Famotidine can be decreased when combined with Pantoprazole.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Pantoprazole.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Pantoprazole.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Pantoprazole.
FluconazoleThe serum concentration of Pantoprazole can be increased when it is combined with Fluconazole.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Pantoprazole.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Pantoprazole.
FlutamideThe metabolism of Flutamide can be decreased when combined with Pantoprazole.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Pantoprazole.
FluvoxamineThe metabolism of Pantoprazole can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Pantoprazole.
FosamprenavirThe metabolism of Pantoprazole can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Pantoprazole can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Pantoprazole can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Pantoprazole can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Pantoprazole.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Pantoprazole.
GemfibrozilThe metabolism of Pantoprazole can be decreased when combined with Gemfibrozil.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Pantoprazole.
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Pantoprazole.
GlyburideThe metabolism of Glyburide can be decreased when combined with Pantoprazole.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Pantoprazole.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Pantoprazole.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Pantoprazole.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Pantoprazole.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Pantoprazole.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Pantoprazole.
IbandronateThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Pantoprazole.
IdelalisibThe serum concentration of Pantoprazole can be increased when it is combined with Idelalisib.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Pantoprazole.
ImatinibThe metabolism of Pantoprazole can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Pantoprazole.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Pantoprazole.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Pantoprazole.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Pantoprazole.
IndinavirThe metabolism of Pantoprazole can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Pantoprazole.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Pantoprazole.
IsavuconazoniumThe metabolism of Pantoprazole can be decreased when combined with Isavuconazonium.
IsoniazidThe metabolism of Pantoprazole can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Pantoprazole can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Pantoprazole.
ItraconazoleThe metabolism of Pantoprazole can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Pantoprazole can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Pantoprazole.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Pantoprazole.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Pantoprazole.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Pantoprazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Pantoprazole.
KetoconazoleThe metabolism of Pantoprazole can be decreased when combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Pantoprazole.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Pantoprazole.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Pantoprazole.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Pantoprazole.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Pantoprazole.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Pantoprazole.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Pantoprazole.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Pantoprazole.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Pantoprazole.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Pantoprazole.
LidocaineThe metabolism of Pantoprazole can be decreased when combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Pantoprazole.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Pantoprazole.
LopinavirThe metabolism of Pantoprazole can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Pantoprazole.
LosartanThe serum concentration of Losartan can be increased when it is combined with Pantoprazole.
LovastatinThe metabolism of Pantoprazole can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Pantoprazole can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Pantoprazole can be decreased when it is combined with Lumacaftor.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Pantoprazole.
MacitentanThe metabolism of Macitentan can be decreased when combined with Pantoprazole.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Pantoprazole.
MelatoninThe metabolism of Melatonin can be decreased when combined with Pantoprazole.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Pantoprazole.
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Pantoprazole.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Pantoprazole.
MethadoneThe metabolism of Methadone can be decreased when combined with Pantoprazole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Pantoprazole.
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Pantoprazole.
MethylphenidatePantoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Pantoprazole.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Pantoprazole.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Pantoprazole.
MexiletineThe metabolism of Pantoprazole can be decreased when combined with Mexiletine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Pantoprazole.
MifepristoneThe metabolism of Pantoprazole can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Pantoprazole.
MitotaneThe serum concentration of Pantoprazole can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Pantoprazole.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Pantoprazole.
ModafinilThe serum concentration of Pantoprazole can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Morphine can be increased when it is combined with Pantoprazole.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pantoprazole.
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pantoprazole.
NadololThe serum concentration of Nadolol can be increased when it is combined with Pantoprazole.
NafcillinThe serum concentration of Pantoprazole can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Pantoprazole.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Pantoprazole.
NefazodoneThe metabolism of Pantoprazole can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Pantoprazole resulting in a loss in efficacy.
NelfinavirThe metabolism of Pantoprazole can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Pantoprazole can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Pantoprazole can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Pantoprazole.
NicardipineThe metabolism of Pantoprazole can be decreased when combined with Nicardipine.
NicotineThe metabolism of Nicotine can be decreased when combined with Pantoprazole.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Pantoprazole.
NilotinibThe metabolism of Pantoprazole can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Pantoprazole.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Pantoprazole.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Pantoprazole.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Pantoprazole.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Pantoprazole.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Pantoprazole.
OlaparibThe metabolism of Pantoprazole can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Pantoprazole.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Pantoprazole.
OsimertinibThe serum concentration of Pantoprazole can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Pantoprazole.
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Pantoprazole.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Pantoprazole.
PalbociclibThe serum concentration of Pantoprazole can be increased when it is combined with Palbociclib.
PamidronateThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Pantoprazole.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Pantoprazole.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Pantoprazole.
Peginterferon alfa-2bThe serum concentration of Pantoprazole can be increased when it is combined with Peginterferon alfa-2b.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Pantoprazole.
PentobarbitalThe metabolism of Pantoprazole can be increased when combined with Pentobarbital.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Pantoprazole.
PethidineThe metabolism of Pethidine can be decreased when combined with Pantoprazole.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Pantoprazole.
PhenobarbitalThe metabolism of Pantoprazole can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Pantoprazole.
PhenytoinThe metabolism of Pantoprazole can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Pantoprazole.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Pantoprazole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Pantoprazole.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Pantoprazole.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Pantoprazole.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Pantoprazole.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Pantoprazole.
PosaconazoleThe metabolism of Pantoprazole can be decreased when combined with Posaconazole.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Pantoprazole.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Pantoprazole.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Pantoprazole.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Pantoprazole.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Pantoprazole.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Pantoprazole.
PrimidoneThe metabolism of Pantoprazole can be increased when combined with Primidone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Pantoprazole.
ProguanilThe metabolism of Proguanil can be decreased when combined with Pantoprazole.
PromazineThe metabolism of Promazine can be decreased when combined with Pantoprazole.
PropofolThe metabolism of Propofol can be decreased when combined with Pantoprazole.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Pantoprazole.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Pantoprazole.
QuazepamThe metabolism of Quazepam can be decreased when combined with Pantoprazole.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Pantoprazole.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Pantoprazole.
QuinineThe serum concentration of Quinine can be increased when it is combined with Pantoprazole.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Pantoprazole.
RaltegravirThe serum concentration of Raltegravir can be increased when it is combined with Pantoprazole.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Pantoprazole.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Pantoprazole.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Pantoprazole.
RanolazineThe metabolism of Pantoprazole can be decreased when combined with Ranolazine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Pantoprazole.
RifabutinThe metabolism of Pantoprazole can be increased when combined with Rifabutin.
RifampicinThe metabolism of Pantoprazole can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Pantoprazole.
RifapentineThe metabolism of Pantoprazole can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Pantoprazole.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Pantoprazole.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Pantoprazole.
RisedronateThe therapeutic efficacy of Risedronate can be decreased when used in combination with Pantoprazole.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Pantoprazole.
RitonavirThe metabolism of Pantoprazole can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Pantoprazole.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Pantoprazole.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Pantoprazole.
RopiniroleThe metabolism of Pantoprazole can be decreased when combined with Ropinirole.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Pantoprazole.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Pantoprazole.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Pantoprazole.
SaquinavirThe metabolism of Pantoprazole can be decreased when combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Pantoprazole.
SelegilineThe metabolism of Selegiline can be decreased when combined with Pantoprazole.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Pantoprazole.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Pantoprazole.
SertralineThe metabolism of Sertraline can be decreased when combined with Pantoprazole.
SildenafilThe metabolism of Pantoprazole can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Pantoprazole.
SiltuximabThe serum concentration of Pantoprazole can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Pantoprazole can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Pantoprazole.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Pantoprazole.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Pantoprazole.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Pantoprazole.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Pantoprazole.
St. John's WortThe serum concentration of Pantoprazole can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Pantoprazole can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Pantoprazole can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Pantoprazole.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Pantoprazole.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Pantoprazole.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Pantoprazole.
Technetium Tc-99m MedronateThe therapeutic efficacy of Technetium Tc-99m Medronate can be decreased when used in combination with Pantoprazole.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Pantoprazole.
TelaprevirThe metabolism of Pantoprazole can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Pantoprazole.
TelithromycinThe metabolism of Pantoprazole can be decreased when combined with Telithromycin.
TemazepamThe metabolism of Temazepam can be decreased when combined with Pantoprazole.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Pantoprazole.
TeniposideThe metabolism of Teniposide can be decreased when combined with Pantoprazole.
TenofovirThe metabolism of Pantoprazole can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Pantoprazole.
TeriflunomideThe serum concentration of Pantoprazole can be decreased when it is combined with Teriflunomide.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Pantoprazole.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Pantoprazole.
TheophyllineThe metabolism of Pantoprazole can be decreased when combined with Theophylline.
ThioridazineThe metabolism of Thioridazine can be decreased when combined with Pantoprazole.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Pantoprazole.
TiclopidineThe metabolism of Pantoprazole can be decreased when combined with Ticlopidine.
TiludronateThe therapeutic efficacy of Tiludronate can be decreased when used in combination with Pantoprazole.
TimololThe serum concentration of Timolol can be increased when it is combined with Pantoprazole.
TipranavirThe serum concentration of Pantoprazole can be decreased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Pantoprazole.
TocilizumabThe serum concentration of Pantoprazole can be decreased when it is combined with Tocilizumab.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Pantoprazole.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Pantoprazole.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Pantoprazole.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Pantoprazole.
TopiramateThe metabolism of Pantoprazole can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Pantoprazole.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Pantoprazole.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Pantoprazole.
TranylcypromineThe metabolism of Pantoprazole can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Pantoprazole.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Pantoprazole.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Pantoprazole.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Pantoprazole.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Pantoprazole.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Pantoprazole.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Pantoprazole.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Pantoprazole.
VemurafenibThe serum concentration of Pantoprazole can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Pantoprazole can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Pantoprazole.
VerapamilThe metabolism of Pantoprazole can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Pantoprazole.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Pantoprazole.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Pantoprazole.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Pantoprazole.
VoriconazoleThe serum concentration of Pantoprazole can be increased when it is combined with Voriconazole.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Pantoprazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Pantoprazole.
WarfarinThe metabolism of Warfarin can be decreased when combined with Pantoprazole.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Pantoprazole.
ZiprasidoneThe metabolism of Pantoprazole can be decreased when combined with Ziprasidone.
Zoledronic acidThe therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Pantoprazole.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Pantoprazole.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium-exchanging atpase activity
Specific Function:
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name:
ATP4A
Uniprot ID:
P20648
Molecular Weight:
114117.74 Da
References
  1. Moreira Dias L: Pantoprazole: a proton pump inhibitor. Clin Drug Investig. 2009;29 Suppl 2:3-12. doi: 10.2165/1153121-S0-000000000-00000. [PubMed:19938880 ]
  2. Cheer SM, Prakash A, Faulds D, Lamb HM: Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003;63(1):101-33. [PubMed:12487624 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. [PubMed:11770010 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11. [PubMed:15313923 ]
  2. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159 ]
  3. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH: Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos. 2009 Apr;37(4):917-23. doi: 10.1124/dmd.108.024901. Epub 2009 Jan 12. [PubMed:19139163 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 24, 2016 03:31